Capstone Investment Advisors
RPRX icon

Capstone Investment Advisors’s Royalty Pharma RPRX Stock Holding History

Capstone Investment Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,481
Closed -$695K – 1877
2026
Q1 		$695K Buy
+14,481
New +$634K ﹤0.01% 997
2025
Q4 		– Sell
-169,255
Closed -$5.97M – 1981
2025
Q3 		$5.97M Buy
169,255
+150,455
+800% +$5.45M 0.01% 431
2025
Q2 		$677K Buy
+18,800
New +$623K ﹤0.01% 1001
2024
Q2 		– Sell
-17,841
Closed -$542K – 2407
2024
Q1 		$542K Buy
+17,841
New +$526K ﹤0.01% 1511
2023
Q4 		– Sell
-7,700
Closed -$209K – 2358
2023
Q3 		$209K Buy
+7,700
New +$229K ﹤0.01% 1794

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capstone Investment Advisors's RPRX Position: Q2 2026 in Review

Capstone Investment Advisors sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 14,481 shares — an estimated $695K sold.

Capstone Investment Advisors first reported a position in RPRX in Q3 2023 and held it in 5 quarters. The position peaked at $5.97M in Q3 2025. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Capstone Investment Advisors reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
  • Capstone Investment Advisors sold 14,481 Royalty Pharma shares in Q2 2026, an estimated $695K.
  • Capstone Investment Advisors first reported a position in Royalty Pharma in Q3 2023 and held it in 5 quarters.
  • Capstone Investment Advisors's Royalty Pharma position peaked at $5.97M in Q3 2025.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.